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A: Supplementary tables and figures 
 
Table A1. Characteristics of study area according to the census. 
 Month of rollout of PPF-LLINs  
 June 
2014 
July 
2014 
Aug 
2014 
Sept 
2014 
June 
2015 
July 
2015 
Aug 
2015 
Sept 
2015 
Total 
Number of clusters 5 5 5 5 5 5 5 5 40 
Number of villages 10 11 11 12 11 13 15 8 91 
Number of 
households 
812 1004 917 842 517 546 685 739 6062 
Population 8739 7620 9505 8597 5758 6170 8043 9054 63486 
Children aged 6-35 
months 
880 717 905 872 564 621 796 892 6247 
Children aged 3-5 
years 
663 564 738 713 505 504 644 748 5079 
Values are numbers.  
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Table A2. Characteristics of replacement children enrolled into the cohort at the third survey (May 2015).  
 Month of rollout of PPF-LLINs  
Characteristics June 2014 July 2014 Aug 2014 Sept 2014 June 2015 July 2015 Aug 2015 Sept 2015 Total  
Children 
enrolled, N 
73 63 99 84 101 76 84 95 675 
Female, N (%) 41/73 (56%) 33/63 (52%) 50/99 (51%) 41/84 (49%) 54/101 (53%) 41/76 (54%) 35/84 (42%) 47/95 (49%) 342/675 (51%) 
Age (months), 
median (IQR) 30 (21,39) 29 (21,43) 30 (18,41) 29 (20,41) 29 (17,40) 29 (19,46) 34 (24,47) 29 (21,40) 29 (20,42) 
Sleeps under a 
mosquito net, N 
(%) 
73/73 (100%) 61/63 (97%) 99/99 (100%) 84/84 (100%) 100/101 (99%) 75/76 (99%) 83/84 (99%) 94/95 (99%) 669/675 (99%) 
Took anti-
malarials in last 
14 days, N (%) 
0/73 (0%) 1/63 (2%) 0/99 (0%) 2/84 (2%) 1/101 (1%) 1/76 (1%) 0/84 (0%) 0/95 (0%) 5/675 (1%) 
Sick with a 
fever during 
previous 48 
hours, N (%) 
1/73 (1%) 4/63 (6%) 4/99 (4%) 11/84 (13%) 2/101 (2%) 4/76 (5%) 1/84 (1%) 2/95 (2%) 29/675 (4%) 
Axillary 
temperatures 
(°C), median 
(IQR) 36.4 (36.2,36.5) 36.4 (36.2,36.7) 36.3 (36.2,36.7) 36.5 (36.2,36.9) 36.4 (36.2,36.8) 36.4 (36.2,36.8) 36.5 (36.2,36.7) 36.5 (36.2,36.8) 36.4 (36.2,36.7) 
Positive rapid 
diagnostic test, 
N (%) 
1/1 (100%) 3/6 (50%) 3/4 (75%) 7/12 (58%) 3/3 (100%) 4/6 (67%) 0/1 (0%) 3/4 (75%) 24/37 (65%) 
Presence of 
Plasmodium 
falciparum 
parasites by 
microscopy, N 
(%) 
26/73 (36%) 29/62 (47%) 47/98 (48%) 40/83 (48%) 50/99 (51%) 31/71 (44%) 38/83 (46%) 44/95 (46%) 305/664 (46%) 
>5000 
Plasmodium 
falciparum 
parasites per μl, 
N (%) 
6/73 (8%) 9/62 (15%) 7/98 (7%) 15/83 (18%) 19/99 (19%) 12/71 (17%) 5/83 (6%) 13/95 (14%) 86/664 (13%) 
Plasmodium 
falciparum 
parasite density 
(per μl), 
geometric mean 
(geometric SD) 
of non-zero 
values 
2162 (5·3) 2043 (4·8) 1634 (5·1) 2923 (6·0) 2865 (6·8) 3203 (5·9) 1293 (3·6) 2308 (5·7) 2211 (5·5) 
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Presence of 
Plasmodium 
falciparum 
gametocytes, N 
(%) 
3/73 (4%) 4/62 (6%) 6/98 (6%) 4/83 (5%) 6/99 (6%) 4/71 (6%) 7/83 (8%) 5/95 (5%) 39/664 (6%) 
Haemoglobin 
level (g/L), 
median (IQR) 
112.0 
(107.0,115.0) 
101.0 
(94.0,111.0) 103.0 (98.0,111.0) 105.0 (99.0,111.0) 102.0 (96.0,111.0) 103.5 (96.0,111.0) 102.0 (99.0,110.0) 
103.0 
(100.0,109.0) 
104.0 
(99.0,111.0) 
Moderate 
anaemia 
(haemoglobin 
<80 g/L), N 
(%) 
2/73 (3%) 4/57 (7%) 2/99 (2%) 3/84 (4%) 6/101 (6%) 4/76 (5%) 1/83 (1%) 3/95 (3%) 25/668 (4%) 
Severe anaemia 
(haemoglobin 
<50 g/L), N 
(%) 
0/73 (0%) 0/63 (0%) 0/99 (0%) 0/84 (0%) 0/101 (0%) 0/76 (0%) 0/84 (0%) 0/95 (0%) 0/668 (0%) 
Enlarged spleen 
(defined as 
score >0 using 
Hackett 
classification), 
N (%) 
6/73 (8%) 1/63 (2%) 0/99 (0%) 1/84 (1%) 3/101 (3%) 3/76 (4%) 7/84 (8%) 0/95 (0%) 21/675 (3%) 
IQR, interquartile range.  
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Table A3. Incidence of clinical malaria in the cohort: unadjusted and adjusted regression models. 
Model adjusted for [1] 
RR (95% CI) for PPF-LLINs 
vs. standard LLINs 
P value for PPF-LLINs vs. 
standard LLINs 
P value for adjustment 
variable 
AIC 
Nothing  0·72 (0·66,0·78) <0·001 -  
Calendar month [2] 0·89 (0·78,1·01) 0·07 <0·001  
Calendar month and health facility [2,3] 0·88 (0·77,0·99) 0·04 
Month: <0·001 
Health facility: <0·001 
27361 
All the following adjusted for calendar month [2], health facility and:     
Age (categorised) 0·87 (0·77,0·99) 0·04 <0·001  
When joined the cohort (survey 1 or 3) 0·87 (0·77,0·98) 0·03 <0·001  
Coverage (whether slept under bed net last night, defined at entry into the 
cohort) 
0·88 (0·77,0·99) 0·04 0·84  
Cluster size, defined by number of children per cluster 0·88 (0·77,0·99) 0·04 0·33  
Random effect for village, instead of cluster  0·86 (0·76,0·97) 0·02 -  
Alterative adjustments for time (all adjusted for health facility):     
Year only (2014, 2015), ignoring month  0·95 (0·86,1·05) 0·29  28494 
Month only (May, June, …, Dec), ignoring year 0·72 (0·66,0·79) <0·001  27463 
Month and year as separate variables (May, June, …, Dec; and 2014, 2015) 0·87 (0·77,0·99) 0·03  27449 
Repeating with ONLY months where there are data from both arms (all 
adjusted for health facility): 
    
Calendar month [2] 0·86 (0·73,1·01) 0·07  16656 
Year only (2014, 2015), ignoring month  1·04 (0·88,1·22) 0·69  17220 
Month only (May, June, …, Dec), ignoring year) 0·86 (0·74,1·00) 0·05  16654 
Month and year as separate variables (May, June, …, Dec; and 2014, 2015) 0·86 (0·73,1·01) 0·07  16656 
AIC=Akaike information criterion. [1] Poisson models with offset for exposure time (natural log transformed), with random interce pt for cluster (unless otherwise indicated). 
[2] Calendar month defined as May 2014, June 2014, …, Dec 2015. [3] This is the model reported in the final column of Table 3 
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Table A4. Secondary and tertiary endpoints at the second cross-sectional survey, by arm: stratified by aged <30 versus ≥30 months.  
 Aged <30 months Aged ≥30 months 
Characteristics 
Standard LLINs 
(n=520) 
PPF-LLINs 
(n=578) 
O dds ratio (OR) or 
coefficient (95% CI; p) 
[1] 
Standard LLINs 
(n=1279) 
PPF-LLINs 
(n=1296) 
O dds ratio (OR) or 
coefficient (95% CI; p) 
[1] 
Presence of Plasmodium falciparum parasites by 
microscopy, N (%) 
274/511 (54%) 300/571 (53%) 
OR=0·92 (0·65,1·28; 
p=0·61) 
822/1250 (66%) 824/1272 (65%) 
OR=0·94 (0·75,1·18; 
p=0·60) 
>5000 Plasmodium falciparum parasites per μl, N 
(%) 
104/511 (20%) 112/571 (20%) 
OR=0·93 (0·68,1·25; 
p=0·62) 
254/1250 (20%) 226/1272 (18%) 
OR=0·84 (0·68,1·02; 
p=0·08) 
Haemoglobin level (g/L), mean (SD) 95·4 (14·38) 99·3 (11·81) 
Coefficient=3·5 (0·9,6·1; 
p=0·008) 
103·8 (12·87) 105·3 (11·23) 
Coefficient=1·2  
(-1·1,3·5; p=0·29) 
Moderate anaemia (haemoglobin <80 g/L), N (%) 66/512 (13%) 32/544 (6%) 
OR=0·41 (0·19,0·84; 
p=0·02) 
47/1256 (4%) 22/1238 (2%) 
OR=0·48 (0·26,0·91; 
p=0·02) 
Severe anaemia (haemoglobin <50 g/L), N (%) 4/512 (1%) 0/544 (0%) Not estimable 3/1256 (0%) 0/1238 (0%) Not estimable 
Enlarged spleen (defined as score >0 using 
Hackett classification), N (%) 
148/520 (28%) 146/578 (25%) OR=1.00 (0.16,6.45; 
p=1.00) 
382/1279 (30%) 275/1296 (21%) OR=0.66 (0.09,4.86; 
p=0.68) 
Analyses stratified by age were pre-specified for haemoglobin levels but not for the other secondary outcomes. Includes cohort and additional children, but excluding children 
during the month of and month after the introduction of the intervention. [1] Odds ratio or coefficient with 95% confidence interval and p-value for PPF-LLINs versus 
standard LLINs, using logistic and linear regression models for categorical and continuous variables, respectively, with cluster as a random effect and  health facility as a 
fixed effect.  
 
 
Table A5. Secondary and tertiary endpoints at the second cross-sectional survey, by arm: stratified by cohort versus additional children.  
 Cohort children (survey 2) Additional children (survey 2) 
Characteristics 
Standard LLINs 
(n=887) 
PPF-LLINs 
(n=908) 
O dds ratio (OR) or 
coefficient (95% CI; p) 
[1] 
Standard LLINs 
(n=912) 
PPF-LLINs 
(n=966) 
O dds ratio (OR) or 
coefficient (95% CI; p) 
[1] 
Presence of Plasmodium falciparum parasites by 
microscopy, N (%) 
475/866 (55%) 494/892 (55%) 
OR=1·03 (0·80,1·32; 
p=0·84) 
621/895 (69%) 630/951 (66%) 
OR=0·82 (0·64,1·05; 
p=0·12) 
>5000 Plasmodium falciparum parasites per μl, N 
(%) 
146/866 (17%) 150/892 (17%) 
OR=1·00 (0·77,1·28; 
p=0·98) 
212/895 (24%) 188/951 (20%) 
OR=0·80 (0·61,·0·96; 
p=0·02) 
Haemoglobin level (g/L), mean (SD) 101·7 (13·78) 104·4 (11·78) 
Coefficient=2·2 (0·0,4·4; 
p=0·05) 
101 (13·9) 103 (11·6) 
Coefficient=1·5  
(-1·0,4·0; p=0·23) 
Moderate anaemia (haemoglobin <80 g/L), N (%) 50/875 (6%) 25/868 (3%) 
OR=0·52 (0·30,0·88; 
p=0·02) 
63/893 (7%) 29/914 (3%) 
OR=0·48 (0·20,1·16; 
p=0·10) 
Severe anaemia (haemoglobin <50 g/L), N (%) 3/875 (0%) 0/868 (0%) Not estimable 4/893 (0%) 0/914 (0%) Not estimable 
Enlarged spleen (defined as score >0 using 
Hackett classification), N (%) 
248/887 (28%) 208/908 (23%) OR=1.82 (0.17,19.2; 
p=0.62) 
282/912 (31%) 213/966 (22%) OR=0.43 (0.06,3.29; 
p=0.42) 
Analyses stratified by cohort versus additional children were not pre-specified but were performed to check whether there were important differences between the children 
later enrolled as replacements compared to those enrolled at the start of the study. Includes cohort and additional children, but excluding children during the month of and 
month after the introduction of the intervention. [1] Odds ratio or coefficient with 95% confidence interval and p-value for PPF-LLINs versus standard LLINs, using logistic 
and linear regression models for categorical and continuous variables, respectively, with cluster as a random effect  and health facility as a fixed effect. 
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Table A6. Adverse events (AEs).  
 Standard LLINs PPF-LLINs Total 
Number of children with at least one AE 11 1 12 
Number of AEs 21 [1] 1 [2] 22 
Diagnosis    
Bronchitis  2 1 3 
Conjunctivitis  1 0 1 
Eye pruritus  1 0 1 
Pelvic pain 2 0 2 
Pruritus  6 0 6 
Rhinitis 5 0 5 
Cough  3 0 3 
Watering eyes 1 0 1 
Severity     
Mild  13 1 14 
Moderate  8 0 8 
Relationship to study     
None  16 0 16 
Related  5 1 6 
Outcome    
Resolved  21 1 22 
Action taken    
None 5 0 5 
Medication  16 1 17 
Presented by arm at time of AE. [1] One child had cough, followed the next day by watering eyes . One child 
had rhinitis and cough, followed by rhinitis again one month later. One child had pruritus , followed the next day 
by rhinitis. One child had pruritus  on two consecutive days, followed two days later by cough and pelvic pain, 
followed the next day by rhinitis . One child had bronchitis , followed two days later by conjunctivitis. One child 
had pruritus twice, approximately two months apart. [2] AE occurred <1 month after rollout of PPF-LLINs.  
 
 
Table A7. Serious adverse events (SAEs).  
 Standard LLINs PPF-LLINs Total 
Number of children with at least one SAE 9 9 18 
Number of SAEs 10 [1] 9 [2] 19 
Diagnosis    
Severe malaria 6 1 7 
Severe malaria and pneumonia 0 1 1 
Severe malaria and urinary infection 1 0 1 
Severe malaria and skin infection 0 1 1 
Uncomplicated malaria and vomiting 1 0 1 
Gastro-enteritis and severe dehydration 0 1 1 
Pneumonia 1 0 1 
No information 1 5 6 [3] 
Type of SAE     
Died  1 5 6 
Hospitalisation 9 4 13 
Presented by arm at time of SAE. [1] One child was diagnosed with severe malaria followed by pneumonia two 
months later (both before rollout of PPF-LLINs in her village). [2] Median time since rollout of PPF-LLINs at 
the time of the SAE was 1.5 months (IQR 0.03 to 11 months). [3] All deaths.  
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Table A8. Pregnancies.  
 Standard LLINs PPF-LLINs Total 
Number of pregnancies  602 961 1563 
Delivery     
Normal 594 (99%) 935 (97%) 1529 (98%) 
Forceps/Ventouse 1 (<1%) 0 (0%) 1 (<1%) 
Caesarean section  0 (0%) 3 (0%) 3 (<1%) 
Spontaneous abortion  1 (<1%) 8 (1%) 9 (1%) 
Missing  6 (1%) 15 (2%) 21 (1%) 
Neonate     
Normal 591 (98%) 914 (95%) 1505 (96%) 
Abnormal 1 (<1%) 6 (1%) 7 (<1%) 
Still born 3 (<1%) 13 (1%) 16 (1%) 
Missing [1] 7 (1%) 28 (3%) 35 (2%) 
Low birth weight (<2.5 kg) 29 (5%)  62 (7%) 91 (6%) [2] 
 
Presented by arm at time of delivery. [1] Includes those with missing delivery information and spontaneous 
abortion. [2] Missing for 10 and 46 pregnancies in the standard LLIN and PPF-LLIN groups, respectively 
(percentages are of non-missing values).   
 
 
Table A9. Asthma.  
 Standard LLINs PPF-LLINs 
Number of children with asthma [1] 40 15 
Score   
<15 (asthma not under control) 0 0 
15-19 (asthma partially under control) 4 (10%) 3 (20%) 
20-25 (asthma under control) 36 (90%) 12 (80%) 
 
For study subjects  identified with asthma, we used the asthma control test method to monitor them for the 
month following the net donation (standard or PPF LLINs) to document any aggravation of symptoms .1 33 
children had data only from the period during which they were in the standard LLIN arm, 8 children had data 
only from the period during which they were in the PPF-LLIN arm, and 7 children had data from both the period 
during which they were in the standard LLIN arm and during which they were in the PPF-LLN arm (these 
children contribute data to both columns). For multiple visits for the same child within one arm of the trial, the 
mean score was taken. The median number of visits per child was 5.5 and 4 within the standard and PPF-LLN 
arms, respectively (range 1-8 and 1-7, respectively).  
 
Whilst the number of serious adverse events were similar in both study arms, there were fewer adverse events in 
the PPF-LLIN arm than with standard LLINs. In absolute numbers there were more spontaneous abortions in 
women with PPF-LLINs than standard LLINs, although this was not statistically significant (Fisher’s exact test, 
p = 0.08), nor was clustering considered in the analysis . There were fewer children with asthma in the PPF-
LLIN arm than those with standard LLINs, with no children having asthma that could not be controlled by 
therapy.  
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Figure A1. Roll out of the pyriproxyfen and permethrin long-lasting insecticidal nets.  
Grey lines indicate cluster boundaries, defined by villages or groups of neighbouring villages with at least 50 
children aged 6 months to 5 years. The colours indicate the order of the rollout of the pyriproxyfen and 
permethrin long-lasting insecticidal nets. There are 40 clusters, and the rollout was performed in 8 rounds (5 
clusters per round) with order randomly assigned.  
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Figure A2. Malaria events outside the study area.  
Malaria events defined by positive rapid diagnostic test.  
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B: Operating characteristics of different parasitaemia cutoffs  
 
Introduction 
 
In areas highly endemic for Plasmodium falciparum, many individuals who have no acute symptoms of the 
disease carry malaria parasites in their blood. The detection of parasites in patients presenting with fever is often 
used as an operational definition of clinical malaria in epidemiological studies and field trials. In such areas, 
some patients so diagnosed as clinical malaria are suffering from fevers  of non-malaria etiology, but are 
considered as clinical malaria cases because of incidental parasitaemia. This leads to overestimation of the 
number of cases, and reduces the specificity of the definition of clinical malaria, leading to a downward bias in  
estimates of efficacy in comparative field trials. 
 
The specificity of the case-definition can be improved by imposing a requirement for parasite densities in fever 
patients to exceed a threshold value, before classifying them as clinical malaria (often a  cut-off of 5000 
parasites/μl, as determined by microscopy is used).  Formal statistical analysis of the quantitative relationship 
between disease incidence and parasite density can be carried out to estimate the operating characteristics of 
different thresholds.2 This is achieved by comparing the distribution of parasite densities in population surveys, 
with that in fever patients. This analysis also provides an estimate of the proportion of the malaria attributable 
fraction of fevers, 𝜆.  
 
This document reports the application of this analysis to the data of the pyriproxyfen net trial. The sensitivities, 
specificities, and attributable fractions were estimated separately for each arm of the trial. The values obtained 
are used to estimate the bias in effectiveness estimates that would apply if different density thresholds were 
adopted. The analysis also provides an estimate of effectiveness that avoids these biases by using the attributable 
fractions to estimate the numbers of clinical malaria episodes in each arm, without the need to classify each 
individual patient.  
 
Methods 
 
The analytical approach treats the parasite densities for fever patients, 𝑥1,𝑥2,… 𝑥𝑛 , as a sample from a mixture 
with two components, 𝜃 (corresponding to negative samples equivalent to control (population survey) samples) 
and 𝜙 (corresponding to positive samples with higher values of x than the controls) so that: 
 
𝑝𝑖 = (1 − 𝜆 𝑖)𝜃𝑖 + 𝜆 𝑖𝜙𝑖  (C1) 
 
where:𝑝𝑖 = 𝑃(𝑥 𝜖 𝑐𝑎𝑡𝑒𝑔𝑜𝑟𝑦  𝑖); 𝜃𝑖 = 𝑃(𝑥 𝜖 𝑐𝑎𝑡𝑒𝑔𝑜𝑟𝑦 𝑖 | 𝑥 𝜖 𝜃);  𝜙𝑖 = 𝑃(𝑥 𝜖 𝑐𝑎𝑡𝑒𝑔𝑜𝑟𝑦 𝑖 | 𝑥 𝜖 𝜙); and 𝜆 𝑖is the 
probability that a fever case in category i has true malaria etiology (this increases with i Aparasitaemic patients 
cannot be true malaria cases, so 𝜆 1 = 0, making 𝜙𝑖 , 𝜃𝑖 , and 𝜆 𝑖 identifiable. 
 
A latent class model, using the method of Vounatsou et al 3 is used to obtain Bayesian estimates of all the 
quantities in equation C1 using a Markov chain Monte Carlo algorithm in the package WinBUGS.4 The 
WinBUGS code used to fit this model is provided below. 
 
The sensitivities and specificities of different candidate threshold parasite densities can be expressed as 
functions of 𝜙𝑖 , 𝜃𝑖 , and 𝜆 𝑖. For the case definition using the i th parasite density threshold, (corresponding to the 
lower boundary of the category) these are computed as: 
 
sensitivity = ∑ 𝜙𝑗 
𝑘
𝑗=𝑖
, and 
specificity = 1 − ∑ 𝜃𝑗  
𝑘
𝑗=𝑖
∑ 𝑝𝑗  
𝑘
𝑗=𝑖
⁄  
 
where k  is the total number of parasite density categories included in the analysis. Correspondingly, the 
proportion of fever cases that are malaria attributable (the attributable fraction, 𝜆) is computed as:  
 
𝜆 = ∑ 𝜆 𝑖  𝜙𝑖 
𝑘
𝑖 =1
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Using the microscopy results from the trial, the effectiveness estimated using each parasite density threshold, is: 
𝐸𝑖 = 1 −
𝑛𝐶 𝑚𝐼 ∑  𝑝𝑖 ,𝐶  
𝑘
𝑗=𝑖
𝑛𝐼 𝑚𝐶 ∑  𝑝𝑖 ,𝐼  
𝑘
𝑗=𝑖
 
 
where the subscripts C and I refer to the control and intervention arms respectively, the quantities  n and m are 
the total numbers of patients and surveyed individuals in the corresponding arms, and the sums, ∑  𝑝𝑖
𝑘
𝑗=𝑖 , give 
the proportions of fever cases satisfying the case definition. This is the conventional estimate of effectiveness 
(the values of 𝑚𝐼 and 𝑚𝐶  appear in order to scale the corresponding counts of episodes by the person -time-at-
risk, assumed to be proportional to the number of survey attendees). 
 
The estimate of effectiveness that uses the attributable fractions, 𝜆, to estimate the numbers of clinical malaria 
episodes in each arm without classifying each individual patient is then the adjusted effectiveness estimate: 
 
𝐸 = 1 −
𝑛𝐶 𝑚𝐼 𝜆 𝐶
𝑛𝐼 𝑚𝐶 𝜆 𝐼
 
 
Results 
 
The samples used for analysis were grouped into 9 categories of parasite density (Table C1).  
 
Table C1: Numbers of samples included in analysis of parasite densities  
Lower bound of density 
(parasites per µl) 
Cross-sectional surveys Fever cases 
Control Inter-vention Control Inter-vention 
0 2225 3415 324 525 
1 486 753 91 104 
500 388 636 71 86 
1000 499 890 113 120 
2500 419 588 115 113 
5000 311 515 104 121 
10000 279 431 208 270 
25000 88 136 293 317 
50000 81 91 507 660 
Just less than half of the survey samples analysed in each arm were positive by microscopy, and most of the 
positive survey samples had low densities (less than 5000 parasites/μl) (Figure C1).  
 
 
Figure C1: Estimates of 𝜽𝒊(distribution of parasite densities in non-malaria fever or survey samples) 
Error bars correspond to 95% credible intervals; vertical lines to a threshold of any parasitaemia by microscopy.  
 
The constraints that the ratio of malaria:non-malaria cases increases with parasite density, and that fevers in 
aparasitaemic (or sub-patent) patients are assumed to be of non-malaria etiology, lead to estimates of 𝜆 𝑖 that 
increase strongly with parasite density around values of around 5000 parasites/μl (Figure C2).  
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Figure C2: Estimates of the probability cases are malaria attributable, 𝝀𝒊  , by parasite density. 
Shaded envelopes correspond to 95% credible intervals; Colours and vertical lines as per Figure C1. 
 
The overall estimates of the attributable fractions, 𝜆, are 0·609 (95% CI 0·569-0·648) for the control arm, with a 
slightly lower value of 0·528 (95% CI 0·500-0·556) for the intervention arm. 
 
Since values of λi  vary considerably with i, the estimated distributions of parasite densities in the malaria 
attributable fever cases (Figure C3) are very different from those in the surveys.  
 
 
Figure C3: Estimates of 𝝓𝒊 (distribution of parasite densities in true malaria cases) 
Colours and lines as per Figure C1.  
 
At lower densities than around 5000 parasites/μl this, the probabilities that a clinical case is malaria attributable 
at a given density diverge (Figure C2). This is because there was a higher ratio of clinical cases to survey 
samples at these densities in the control arm. However there is little difference between arms in the estimates of 
𝜙𝑖 shown in Figure C3. Correspondingly, the estimates of the sensitivities (Figure C4) and specificities (Figure 
C5) for different parasite density thresholds are similar for both trial arms. 
 
 
Figure C4: Sensitivity of parasite density thresholds 
Colours, shading and vertical lines as Figure C2. 
 
As anticipated, there is a substantial increase in specificity with parasite density, with a threshold value of 
around 5000 parasites/μl required to achieve a specificity above 80% (Figure C5). This implies that many cases 
with low parasite densities included in the primary trial analysis are sick because of causes other than clinical 
malaria.  
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Figure C5: Specificity of parasite density thresholds  
Colours, shading and vertical lines as Figure C2. 
 
The extent to which the inclusion of non-malaria fevers biases the estimate of effectiveness is illustrated by the 
effectiveness estimates made using the different thresholds (Figure C6).  
 
 
Figure C6. Effectiveness estimates made using different thresholds  
Thick black line, unadjusted estimates; red line adjusted estimate; vertical line corresponds to threshold of any 
parasitaemia by microscopy. 
 
Somewhat contrary to expectations, the effectiveness estimates do not increase with the use of higher (more 
specific) thresholds. However, the adjusted estimate of effectiveness of 0·295 (95% CI: 0·232-0·351), (obtained 
by assigning probabilities that fevers are malaria attributable as functions of the parasite density) is higher than 
the effectiveness estimates obtained by using any fixed cutoff. In particular, the estimate obtained using the 
threshold of any parasitaemia by microscopy, of 0·236 is 20% lower than the adjusted value.   This suggests that 
there is a considerable downward bias in the primary efficacy measure because of inclusion of non-malaria 
fevers, but that the fevers with the highest parasite densities were no more likely to be in the control arm than 
were malaria fevers with lower densities.  
 
Discussion and conclusions 
 
There is no evidence in these data of any important imbalances between the arms in terms of the distributions of 
parasite densities in infected individuals, and clinical malaria cases in the two arms have similar parasite density 
distributions.  
 
The specificity of clinical malaria definitions increases with the use of a higher parasite density threshold, as 
expected. Nevertheless with this dataset, the use of a more specific case definition would not lead to a higher 
effectiveness estimate.  
 
At the same time, the analysis sugges ts that the misclassification of cases of non-malaria fever with incidental 
parasitaemia introduces a substantial downward bias in the efficacy estimates. The true effectiveness of the 
intervention in averting clinical malaria is approximately 20% higher than the estimates obtained from the 
primary analysis. 
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Winbugs code 
 
model latentclass 
{  
for (a in 1:arms) { 
 for (i in 1:2){ 
  z0[a,i]<-(i-1)*0.0001 
  phi0[a,i]<-theta[a,i]*z0[a,i] 
 } 
 theta[a,1]<-1-St[a] 
 eltheta[a,1]~ dgamma(1.0,1.0) 
 theta[a,2]<-eltheta[a,2]/(1+Sr[a])  
  eltheta[a,2]~ dgamma(1.0E-2,1.0E-2) 
 for (i in 3:K){  
  phi0[a,i]<-theta[a,i]*z0[a,i]  
  eltheta[a,i]~ dgamma(1.0E-2,1.0E-2) 
  theta[a,i]<-eltheta[a,i]/(1+Sr[a])  
  z0[a,i]<-z0[a,i-1]/q[a,i] 
 }  
 Sn[a]<-sum(n[a,]) 
 Sm[a]<-sum(m[a,]) 
 Sr[a]<-sum(eltheta[a,2:K])  
 St[a]<-sum(theta[a,2:K]) 
 Sp[a]<-sum(p0[a,]) 
 Sphi0[a]<-sum(phi0[a,]) 
 for (i in 1:K){ 
  phi[a,i]<-phi0[a,i]/Sphi0[a] 
  z[a,i]<-z0[a,i]/Sphi0[a] 
  q[a,i]~dunif(0.001,0.999) 
  p0[a,i]<- theta[a,i]*(1-lambda[a])+lambda[a]*phi[a,i] 
  p[a,i]<-p0[a,i]/Sp[a] 
  lami[a,i]<-lambda[a]*phi[a,i]/p0[a,i] 
  } 
# Computation of sensitivities and specificities of cutoffs  
  sens[a,1] <- 1.0 
  spec[a,1] <- 0.0  
  cum_theta[a,1] <- theta[a,1] 
  cum_phi[a,1] <- phi[a,1] 
  cum_p[a,1] <- p[a,1] 
  unadj_cases[a,1] <- Sn[a]/Sm[a] 
  adj_cases[a,1] <- Sn[a]*lambda[a]/Sm[a] 
  for (i in 2:K){ 
  sens[a,i] <- sens[a,i-1]-phi[a,i-1] 
  cum_theta[a,i] <- cum_theta[a,i-1] + theta[a,i] 
  cum_phi[a,i] <- cum_phi[a,i-1] + phi[a,i] 
  cum_p[a,i] <- p[a,i-1] + p[a,i] 
  spec[a,i] <- 1 - (1 - cum_theta[a,i-1])/(1 - cum_p[a,i-1]) 
# Total cases included by threshold,  
# scaled by population at risk (via total of m) 
# adj_ refers to adjustment for incidental parasitaemia  
  unadj_cases[a,i] <- (1 - cum_p[a,i-1])*Sn[a]/Sm[a] 
  adj_cases[a,i]<-(1-cum_phi[a,i-1])*Sn[a]*lambda[a]/Sm[a] 
  } 
  m[a,1:K]~ dmulti(theta[a,1:K], Sm[a]) 
  n[a,1:K]~ dmulti(p[a,1:K], Sn[a]) 
  lambda[a]~ dunif(0.00001,0.99999) 
 }  
# Comparisons between arms by cutoff 
 for (i in 1:K){ 
  unadj_eff[i] <- 1 - unadj_cases[2,i]/unadj_cases[1,i] 
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  adj_eff [i]<- 1 - adj_cases[2,i]/adj_cases[1,i] 
 } 
} 
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C: Estimation of EIR  
 
To model the numbers of female A. gambiae collected per trap, we used a negative binomial model, with village 
cluster as a random effect, and treatment arm, month and health facility as fixed effects. The means by arm were 
estimated marginally over month and health facility, assuming a random effect of zero. We used a logistic 
regression model with the same random and fixed effects to model the sporozoite prevalence, and the 
prevalences by arm were estimated similarly.  
 
For arm i = 0 (standard LLINs) and i = 1 (PPF-LLINS), let HDMi indicate the household density of mosquitoes 
and SPR i  indicate the sporozoite proportion, estimated as described above. Let n represent the number of days in 
the transmission season (n = 214 ). As per the main manuscript, the entomological inoculation rate (EIR) was 
estimated for each arm i as follows: 
 
EIR i = HDMi × SPR i × n 
 
The ratio of the EIR was determined as EIR1/EIR0 .  
 
To estimate 95% confidence intervals , we treated HDMi and SPR i  as independent variables and used an 
asymptotic approximation following Armitage and Berry (1). Let the means of HDMi and SPR i  be denoted μi1 
and μi2, respectively, and their variances σi1  and σi2 , respectively. Then the variances of the product of HDMi 
and SPR i  for each arm i are given by: 
 
var(HDMi  SPR i) = μi1
2 σi2
2 + μi2
2 σi1
2 + σi1
2 σi2
2  
 
We then used a Normal approximation to estimate the confidence intervals for the product HDMi  SPR i , and 
finally multiplied the confidence limits by n = 214.  
 
For the confidence interval of the ratio EIR1 /EIR0 , we used the approximation:  
 
var(EIR 1/EIR 0) =
𝑣𝑎𝑟(EIR1)
𝐸(EIR 0)
2
+
𝐸(EIR 1)
2
𝐸(EIR0 )
4
𝑣𝑎𝑟(EIR 0) 
 
assuming that the coefficient of variation of EIR1 is small (1). We obtained a p-value using a Wald test.  
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D: Insecticide-susceptibility tests.  
Discriminating Dose Assays 
Results of the WHO susceptibility tests performed during the study.  Mosquitoes were collected from three health 
districts in the Cascades region, Burkina Faso. Health districts are specified within brackets. Mosquitoes were 
collected as larvae in July (Tiefora and Bakaridjan in 2014) or October (Naniagara and Bakaridjan 2015). 
  
2014 
 
2015 
Village 
 
Replicate Mortality n 
 
Replicate Mortality n 
Tiefora Centre (Tiefora) 
 
1 2 22 
 
1 0 25 
 
2 4 25 
 
2 1 27 
 
3 6 27 
 
3 0 24 
 
4 1 23 
 
4 0 21 
 
Total 13 97 
 
Total 1 97 
  % mortality 13.4    % mortality 1.03   
         
Naniagara (Kankounadeni) 
 
1 5 29 
 
1 1 27 
 
2 1 25 
 
2 2 27 
 
3 2 26 
 
3 6 23 
 
4 2 19 
 
4 11 24 
  
Total 10 99 
 
Total 20 101 
  % mortality 10.1    % mortality 19.8   
         
Bakaridjan (Koflande) 
 
1 7 21 
 
1 4 24 
 
2 9 22 
 
2 3 29 
 
3 3 18 
 
3 6 31 
 
4 1 26 
 
4 4 31 
 
5 7 30 
 
5 6 22 
  
6 3 18 
 
   
  
7 2 32 
 
   
  Total 32 167  Total 23 137 
  % mortality 19.2    % mortality 16.8   
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Measurements of intensity of permethrin resistance. 
A modified version of the CDC bottles assay was used to estimate the permethrin Lethal Concentration 
50 (LC50), which is the dose that kills 50% of a population for mosquitoes collected from the three 
health districts in October 2013. Bottles were coated internally with different concentrations of 
permethrin (ranging from 5 ppm to 120 ppm) following the procedure described by CDC5  and the 
modifications proposed by Bagi et al 6Four groups of approximately 25 three to five days old female 
mosquitoes were aspirated into the bottles and exposed for 60 min. Mosquitoes were then transferred 
to paper cups with 10% sucrose available, and mortality recorded 24h later. In every experiment control 
bottles impregnated only with the solvent (acetone) were also tested.   
The permethrin LC50 ranged from 17.8 ppm in Bakaridjan mosquitoes to 29.7 ppm in Naniagara 
mosquitoes (Figure D1). There was a significant difference in the LC50 between Bakaridjan and the 
other two sites although the difference between the highest and lowest value was less than 1.7-fold. The 
permethrin LC50 for the Kisumu susceptible strain was previously calculated as 0.284 ppm
6, and thus 
estimates of the resistance ratio of the field populations range from 60.7 to 115.1 fold.  
 
Figure D1 Permethrin LC50. Mortality curve showing the effect of different permethrin (log) concentrations on 
survival of An. gambiae s.l. collected from three sites in 2013. 
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